小儿肿瘤中ctDNA的研究进展

doi:10.3969/j.issn.1004-583X.2025.08.017

摘要/Abstract

摘要：

小儿恶性肿瘤是现如今导致儿童死亡的主要疾病之一,虽然各种治疗手段不断进步,但部分恶性肿瘤的复发和耐药,仍是预后不良的关键因素。循环肿瘤DNA(circulating tumor DNA,ctDNA),为检测血浆中癌症特异性标志物的一种微创工具,越来越受到重视,在成人癌症中,ctDNA检测已显示出在疾病监测应用中的价值,包括肿瘤突变谱分析、风险分层、复发预测和治疗反应评估。目前,ctDNA已在成人多种肿瘤的诊断和治疗效果预测中进行使用且越来越被临床所接受,但在儿童肿瘤的使用目前仍具有一定局限性。本文系统综述ctDNA在小儿肿瘤中的生物学特性、检测技术、临床应用现状及挑战,并结合最新研究探讨其未来发展方向,为推动精准医疗在儿科肿瘤中的应用提供理论依据。

关键词: 肿瘤, 循环肿瘤DNA, 微小残留病灶, 液体活检, 精准医疗

中图分类号:

R739.9

滕怀千, 萧俊, 肖龙敏, 王安琪. 小儿肿瘤中ctDNA的研究进展[J]. 临床荟萃, 2025, 40(8): 764-768.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://www.lchc.cn/CN/10.3969/j.issn.1004-583X.2025.08.017

https://www.lchc.cn/CN/Y2025/V40/I8/764

参考文献 48

[1]	Lupo PJ, Spector LG. Cancer progress and priorities: Childhood cancer[J]. Cancer Epidemiol Biomarkers Prev, 2020, 29(6): 1081-1094.
[2]	Zahnreich S, Schmidberger H. Childhood cancer: Occurrence, treatment and risk of second primary malignancies[J]. Cancers (Basel), 2021, 13(11):2607.
[3]	Keller KM, Koetsier J, Schild L, et al. The potential of PARP as a therapeutic target across pediatric solid malignancies[J]. BMC Cancer, 2023, 23(1): 310. doi: 10.1186/s12885-022-10319-7 pmid: 37020198
[4]	Liu LP, Zong SY, Zhang AL, et al. Early detection of molecular residual disease and risk stratification for children with acute myeloid leukemia via circulating tumor DNA[J]. Clin Cancer Res, 2024, 30(6): 1143-1151. doi: 10.1158/1078-0432.CCR-23-2589 pmid: 38170574
[5]	Yeh JM, Ward ZJ, Chaudhry A, et al. Life expectancy of adult survivors of childhood cancer over 3 decades[J]. JAMA Oncol, 2020, 6(3): 350-357. doi: 10.1001/jamaoncol.2019.5582 pmid: 31895405
[6]	Peterson K, Turos-Cabal M, Salvador AD, et al. Mechanistic insights into medulloblastoma relapse[J]. Pharmacol Ther, 2024, 260: 108673.
[7]	Othman J, Potter N, Ivey A, et al. Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission[J]. Blood, 2024, 143(19): 1931-1936.
[8]	Herbst RS, John T, Grohé C, et al. Molecular residual disease analysis of adjuvant osimertinib in resected EGFR-mutated stage IB-IIIA non-small-cell lung cancer[J]. Nat Med, 2025, 31(6): 1958-1968.
[9]	Doculara L, Trahair TN, Bayat N, et al. Circulating tumor DNA in pediatric cancer[J]. Front Mol Biosci, 2022, 9: 885597.
[10]	Lei S, Jia S, Takalkar S, et al. Genomic profiling of circulating tumor DNA for childhood cancers[J]. Leukemia, 2025, 39(2): 420-430. doi: 10.1038/s41375-024-02461-x pmid: 39523434
[11]	Xu L, Kim ME, Polski A, et al. Establishing the clinical utility of ctDNA analysis for diagnosis, prognosis, and treatment monitoring of retinoblastoma: The aqueous humor liquid biopsy[J]. Cancers (Basel), 2021, 13(6):1282.
[12]	Kahana-Edwin S, Cain LE, Karpelowsky J. Roadmap to liquid biopsy biobanking from pediatric cancers-challenges and opportunities[J]. Biopreserv Biobank, 2021, 19(2): 124-129. doi: 10.1089/bio.2020.0117 pmid: 33493007
[13]	Vellanki PJ, Ghosh S, Pathak A, et al. Regulatory implications of ctDNA in immuno-oncology for solid tumors[J]. J Immunother Cancer, 2023, 11(2):e005344.
[14]	Ni X, Li Z, Li X, et al. Socioeconomic inequalities in cancer incidence and access to health services among children and adolescents in China: A cross-sectional study[J]. Lancet, 2022, 400(10357): 1020-1032. doi: 10.1016/S0140-6736(22)01541-0 pmid: 36154677
[15]	Garcia-Murillas I, Cutts RJ, Walsh-Crestani G, et al. Longitudinal monitoring of circulating tumor DNA to detect relapse early and predict outcome in early breast cancer[J]. Breast Cancer Res Treat, 2025, 209(3): 493-502.
[16]	Fan H, Wang B, Shi L, et al. Monitoring minimal residual disease in patients with multiple myeloma by targeted tracking serum m-protein using mass spectrometry (EasyM)[J]. Clin Cancer Res, 2024, 30(6): 1131-1142. doi: 10.1158/1078-0432.CCR-23-2767 pmid: 38170583
[17]	Diehl F, Schmidt K, Choti MA, et al. Circulating mutant DNA to assess tumor dynamics[J]. Nat Med, 2008, 14(9): 985-990. doi: 10.1038/nm.1789 pmid: 18670422
[18]	De Mattos-Arruda L, Mayor R, Ng CKY, et al. Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma[J]. Nat Commun, 2015, 6: 8839. doi: 10.1038/ncomms9839 pmid: 26554728
[19]	Bosse KR, Giudice AM, Lane MV, et al. Serial profiling of circulating tumor DNA identifies dynamic evolution of clinically actionable genomic alterations in high-risk neuroblastoma[J]. Cancer Discov, 2022, 12(12): 2800-2819. doi: 10.1158/2159-8290.CD-22-0287 pmid: 36108156
[20]	Patel J, Aittaleb R, Doherty R, et al. Liquid biopsy in H3K27M diffuse midline glioma[J]. Neuro Oncol, 2024, 26(Supplement_2): S101-s109.
[21]	Combaret V, Hogarty MD, London WB, et al. Influence of neuroblastoma stage on serum-based detection of MYCN amplification[J]. Pediatr Blood Cancer, 2009, 53(3): 329-331. doi: 10.1002/pbc.22009 pmid: 19301388
[22]	Pagès M, Rotem D, Gydush G, et al. Liquid biopsy detection of genomic alterations in pediatric brain tumors from cell-free DNA in peripheral blood, CSF, and urine[J]. Neuro Oncol, 2022, 24(8): 1352-1363.
[23]	Pierce E, Mautner B, Mort J, et al. MRD in aLL: Optimization and innovations[J]. Curr Hematol Malig Rep, 2022, 17(4): 69-81.
[24]	Bellassai N, D'Agata R, Marti A, et al. Detection of tumor DNA in human plasma with a functional pll-based surface layer and plasmonic biosensing[J]. ACS Sens, 2021, 6(6): 2307-2319.
[25]	Escudero L, Llort A, Arias A, et al. Circulating tumour DNA from the cerebrospinal fluid allows the characterisation and monitoring of medulloblastoma[J]. Nat Commun, 2020, 11(1): 5376. doi: 10.1038/s41467-020-19175-0 pmid: 33110059
[26]	Newman AM, Bratman SV, To J, et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage[J]. Nat Med, 2014, 20(5): 548-554. doi: 10.1038/nm.3519 pmid: 24705333
[27]	Bettegowda C, Sausen M, Leary RJ, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies[J]. Sci Transl Med, 2014, 6(224): 224ra24.
[28]	Liu APY, Smith KS, Kumar R, et al. Serial assessment of measurable residual disease in medulloblastoma liquid biopsies[J]. Cancer Cell, 2021, 39(11): 1519-1530.e4. doi: 10.1016/j.ccell.2021.09.012 pmid: 34678152
[29]	Nelson AJ, Park S, Nelson MD Jr, et al. Aqueous humor liquid biopsy to exclude retinoblastoma for a child with an intraocular mass[J]. Case Rep Ophthalmol, 2025, 16(1): 366-371.
[30]	Conway AM, Pearce SP, Clipson A, et al. A cfDNA methylation-based tissue-of-origin classifier for cancers of unknown primary[J]. Nat Commun, 2024, 15(1): 3292.
[31]	Wu Y, Tilley RD, Gooding JJ. Challenges and solutions in developing ultrasensitive biosensors[J]. J Am Chem Soc, 2019, 141(3): 1162-1170. doi: 10.1021/jacs.8b09397 pmid: 30463401
[32]	Kahana-Edwin S, Cain LE, McCowage G, et al. Neuroblastoma molecular risk-stratification of DNA copy number and ALK genotyping via cell-free circulating tumor DNA profiling[J]. Cancers (Basel), 2021, 13(13):3365.
[33]	Nirgude S, Naveh NSS, Kavari SL, et al. Cancer predisposition signaling in beckwith-wiedemann syndrome drives wilms tumor development[J]. Br J Cancer, 2024, 130(4): 638-650.
[34]	Abbou S, Klega K, Tsuji J, et al. Circulating tumor DNA is prognostic in intermediate-risk rhabdomyosarcoma: A report from the children's oncology group[J]. J Clin Oncol, 2023, 41(13): 2382-2393.
[35]	Adane B, Alexe G, Seong BKA, et al. STAG2 loss rewires oncogenic and developmental programs to promote metastasis in Ewing sarcoma[J]. Cancer Cell, 2021, 39(6): 827-844.e10. doi: 10.1016/j.ccell.2021.05.007 pmid: 34129824
[36]	Klega K, Imamovic-Tuco A, Ha G, et al. Detection of somatic structural variants enables quantification and characterization of circulating tumor DNA in children with solid tumors[J]. JCO Precis Oncol, 2018, 2018:PO.17.00285.
[37]	Saarinen-Pihkala UM, Parto K, Riikonen P, et al. RALLE pilot: Response-guided therapy for marrow relapse in acute lymphoblastic leukemia in children[J]. J Pediatr Hematol Oncol, 2012, 34(4): 263-270. doi: 10.1097/MPH.0b013e3182352da9 pmid: 22246158
[38]	Zhu GQ, Liu WR, Tang Z, et al. Serial circulating tumor DNA to predict early recurrence in patients with hepatocellular carcinoma: A prospective study[J]. Mol Oncol, 2022, 16(2): 549-561.
[39]	Fu Y, Xu Y, Liu W, et al. Tumor-informed deep sequencing of ctDNA detects minimal residual disease and predicts relapse in osteosarcoma[J]. EClinicalMedicine, 2024, 73: 102697.
[40]	Berko ER, Witek GM, Matkar S, et al. Circulating tumor DNA reveals mechanisms of lorlatinib resistance in patients with relapsed/refractory ALK-driven neuroblastoma[J]. Nat Commun, 2023, 14(1): 2601. doi: 10.1038/s41467-023-38195-0 pmid: 37147298
[41]	Leonetti A, Cervati V, Minari R, et al. Liquid biopsy and 18F-FDG PET/CT derived parameters as predictive factors of osimertinib treatment in advanced EGFR-Mutated NSCLC[J]. Clin Lung Cancer, 2024, 25(8): e436-e45.e9.
[42]	Cabús L, Lagarde J, Curado J, et al. Current challenges and best practices for cell-free long RNA biomarker discovery[J]. Biomark Res, 2022, 10(1): 62. doi: 10.1186/s40364-022-00409-w pmid: 35978416
[43]	Godsey JH, Silvestro A, Barrett JC, et al. Generic protocols for the analytical validation of next-generation sequencing-based ctdna assays: A joint consensus recommendation of the BloodPAC's analytical variables working group[J]. Clin Chem, 2020, 66(9): 1156-1166. doi: 10.1093/clinchem/hvaa164 pmid: 32870995
[44]	Mangum R, Reuther J, Sen Baksi K, et al. Circulating tumor DNA sequencing of pediatric solid and brain tumor patients: An institutional feasibility study[J]. Pediatr Hematol Oncol, 2023, 40(8): 719-738.
[45]	Kramer A, Schuuring E, Vessies DCL, et al. A micro-costing framework for circulating tumor DNA testing in dutch clinical practice[J]. J Mol Diagn, 2023, 25(1): 36-45.
[46]	Keup C, Kimmig R, Kasimir-Bauer S. Combinatorial power of cfDNA, CTCs and EVs in oncology[J]. Diagnostics (Basel), 2022, 12(4):870.
[47]	Liu F, Xiong QW, Wang JH, et al. Roles of lncRNAs in childhood cancer: Current landscape and future perspectives[J]. Front Oncol, 2023, 13: 1060107.
[48]	Werutsky G, Barrios CH, Cardona AF, et al. Perspectives on emerging technologies, personalised medicine, and clinical research for cancer control in Latin America and the Caribbean[J]. Lancet Oncol, 2021, 22(11): e488-e500.

小儿肿瘤中ctDNA的研究进展

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 48

相关文章 15

编辑推荐

Metrics

本文评价

[1]	陈文江, 舒展, 周来显. 基于核酸适配体的肺癌诊断和治疗研究进展[J]. 临床荟萃, 2025, 40(8): 742-747.
[2]	潘凌峰, 林芳芳, 杨川. 人工智能在前列腺癌超声诊断中的应用[J]. 临床荟萃, 2025, 40(6): 547-552.
[3]	田晓婷, 卢泽芬. 肺癌患者静脉血栓栓塞危险因素的研究进展[J]. 临床荟萃, 2025, 40(5): 473-476.
[4]	李忠标, 赵习浩, 杜敏, 王江, 于跃, 张佃良. 肠腔内生性卵巢外腹膜浆液性乳头状腺癌1例并文献复习[J]. 临床荟萃, 2025, 40(3): 257-261.
[5]	陈诚, 钱卓宇, 全栩毅, 段圣武. 结直肠癌浆膜及肌层受累影像诊断的研究进展[J]. 临床荟萃, 2025, 40(3): 281-284.
[6]	杜黎辉, 卢航舵, 张文君, 王文华, 王园园, 贾英萍. 儿童实体肿瘤术后心理行为调查及其影响因素[J]. 临床荟萃, 2024, 39(9): 816-820.
[7]	刘嘉珠, 刘蓉, 孟利敏, 郭银树, 张晓博, 艾怡琴. 乳腺癌患者睡眠障碍发生率和影响因素的系统评价[J]. 临床荟萃, 2024, 39(6): 494-500.
[8]	申彤彤, 匡竞, 王玮. 血清肿瘤标志物在肝细胞癌早期诊断中的应用[J]. 临床荟萃, 2024, 39(6): 563-567.
[9]	高铭, 刘昊, 于航, 林霖, 张紫杰, 熊颖. 超声造影对局灶性睾丸病变诊断价值的meta分析[J]. 临床荟萃, 2024, 39(5): 389-395.
[10]	邬晓敏, 方益鹏, 章真, 章烨, 金成. 仑伐替尼联合PD-1单抗及GEMOX方案在晚期胆道恶性肿瘤治疗中的临床观察[J]. 临床荟萃, 2024, 39(5): 408-412.
[11]	王壮壮, 任欢, 刘彦廷, 田春雷, 艾文兵. 基于SEER数据库使用列线图对四肢骨肉瘤发生肺转移风险预测模型的构建与验证[J]. 临床荟萃, 2024, 39(5): 413-419.
[12]	张晓阳, 藏美荣, 锁静, 孟建波, 宋晓宁, 王金铠. 强直性脊柱炎合并急性早幼粒细胞白血病及弥散性血管内凝血1例并文献复习[J]. 临床荟萃, 2024, 39(4): 342-346.
[13]	陈诗雨, 罗专波. 肿瘤相关静脉血栓栓塞症研究进展[J]. 临床荟萃, 2024, 39(4): 363-369.
[14]	陈岚, 李叶琼, 冶秀鹏. 费城染色体阴性骨髓增殖性肿瘤患者血栓形成影响因素[J]. 临床荟萃, 2024, 39(4): 370-375.
[15]	任雷, 刘晔, 鲍书友, 李葵芳. 母细胞性浆细胞样树突细胞肿瘤2例并文献复习[J]. 临床荟萃, 2024, 39(3): 253-258.